Changing the game – Generative artificial intelligence to drive enhanced business outcomes

Organisations seeking to adopt generative AI should be considering five key actions, write Cian Kelliher, Partner, and Alan Lavery, Gen AI Lead with KPMG’s Consulting practice

In pharmaceuticals, AI already touches almost every step of the lifecycle, from drug discovery, clinical trial targeting and synthesised outcomes through to production efficiencies in material sourcing, manufacturing, and logistics.

Generative Artificial Intelligence (GenAI) is a potential game changer for multiple sectors driving enhanced business outcomes in areas such as: